^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Excerpt:
Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab)...Patients with elevated CRP and LDH and a REC <1.5% were at highest risk for disease progression and death (p = 0.001). Blood markers predict survival in metastatic UM treated with immune checkpoint blockade.
DOI:
10.1016/j.ejca.2017.05.038
